Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803

BACKGROUND: The ACCENT group previously established disease-free survival (DFS) with 2 or 3 years median follow-up to predict 5 year overall survival (5yr OS) in stage II and III colon cancer. ACCENT further proposed (1) a stronger association between DFS and OS in stage III than II, and (2) 6 or 7...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sargent, D, Shi, Q, Yothers, G, Van Cutsem, E, Cassidy, J, Saltz, L, Wolmark, N, Bot, B, Grothey, A, Buyse, M, de Gramont, A
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3073413/
https://ncbi.nlm.nih.gov/pubmed/21257306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2010.12.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados